Cardiovascular Drugs And Cancer Risk: A Dissenter’s View
This article was originally published in RPM Report
Here is an excerpt from FDA medical reviewer Thomas Marciniak’s “special review” submitted as part of the record for FDA’s review of Pfizer/Bristol-Myers Squibb’s Eliquis (apixaban). In it, he calls for public discussion of cancer risks associated with anti-clotting drugs like apixaban—and angiotensin receptor blocker antihypertensives. The email exchange released in this review was the basis for media coverage of the “debate” within FDA over the link between ARBs and lung cancer.
You may also be interested in...
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.
It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.